Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for China SXT Pharmaceuticals (SXTC) over the last 9 years, with Mar 2025 value amounting to $18.1 million.

  • China SXT Pharmaceuticals' Cash & Equivalents rose 50.11% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 50.11%. This contributed to the annual value of $18.1 million for FY2025, which is 49.95% up from last year.
  • China SXT Pharmaceuticals' Cash & Equivalents amounted to $18.1 million in FY2025, which was up 49.95% from $12.1 million recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Cash & Equivalents peaked at $18.1 million during FY2025, and registered a low of $12.1 million during FY2024.
  • Over the past 3 years, China SXT Pharmaceuticals' median Cash & Equivalents value was $17.4 million (recorded in 2023), while the average stood at $15.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 83.33% in 2021, then plummeted by 30.50% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Cash & Equivalents (MRY) stood at $13.4 million in 2021, then rose by 16.55% to $15.6 million in 2022, then increased by 11.55% to $17.4 million in 2023, then tumbled by 30.50% to $12.1 million in 2024, then skyrocketed by 49.95% to $18.1 million in 2025.
  • Its Cash & Equivalents was $18.1 million in FY2025, compared to $12.1 million in FY2024 and $17.4 million in FY2023.